Citations

Clear

4206 citation(s) found for "Chen, Yu".

Brain regional susceptibility to tauopathy in individuals at risk for chronic traumatic encephalopathy
Wiegand, Tim L. T., Rubinski, Anna, Jung, Leonard B., Franzmeier, Nicolai, Arciniega, Hector , Ravanfar, Parsa , Alosco, Michael L., Tripodis, Yorghos, Su, Yi, Protas, Hillary, Lin, Alexander P., Pasternak, Ofer, Chen, Kewei, Bouix, Sylvain, Adler, Charles H., Balcer, Laura J. , Bernick, Charles, Cummings, Jeffrey L., Stern, Robert A., Reiman, Eric M., Shenton, Martha E., Ewers, Michael, Wiegand, Tim L. T. , Koerte, Inga K , Rubinski, Anna , Jung, Leonard , Franzmeier, Nicolai , Dewenter, Anna , Alosco, Michael L. , Tripodis, Yorghos , Su, Yi, Protas, Hillary , Pasternak, Ofer , Coleman, Michael , Bouix, Sylvain , Adler, Charles H. , Bernick, Charles , Reiman, Eric M. , Shenton, Martha E. , Ewers, Michael

Mayo Clinic

Alzheimer's & Dementia | June 17, 2026 | Volume: 22 | Issue: 6 | Pages: No page available

10.1002/alz.71503 | PMID 42304137 Get It

Abstract INTRODUCTION Chronic traumatic encephalopathy (CTE) is a tauopathy linked to repetitive head impacts. Factors influencing brain regional susceptibility to tau deposition and spreading remain unclear. METHODS We used three datasets: [18F]flortaucipir positron emission tomography (PET) in 157 former professional American football players and 53 controls (DIAGNOSE CTE); cortical myelin water fractions (MWF) in 50 healthy individuals (Myelin Water Atlas); and white matter (WM) tract MWF and functional connectivity (FC) in 100 healthy individuals (Human Connectome Project). We tested associations between tau‐PET uptake and covariance in football players and typical cortical gray matter (GM) MWF, WM tract MWF, and FC. RESULTS Cortical regions with lower typical GM MWF showed higher tau‐PET uptake ( β = −0.399, p = 0.001). WM tracts with lower typical MWF were associated with higher tau‐PET covariance ( β = −0.238, p < 0.001). Higher typical FC was associated with higher tau‐PET covariance ( β = 0.447, p < 0.001). DISCUSSION In former football players at risk for CTE, regional susceptibility to tau deposition may be driven by low myelin and high FC.
Volume-Staged Stereotactic Radiosurgery in Pediatric Patients With Large Brain Arteriovenous Malformations: An International, Multicenter Study
Hajikarimloo, Bardia , Tos, Salem M., Ferguson, Robert , Chan, Jason W., Sneed, Penny K. , McDermott, Michael W., Seymour, Zachary , Grills, Inga, Reda, Wael A., Tawadros, Sameh R., Abdelkarim, Khaled, Emad, Reem M. , Lunsford, L. Dade, Niranjan, Ajay, Peker, S A, Samanci, Yavuz, Lee, Cheng-chia, Yang, Huai-che, Sheehan, Darrah, Sheehan, Kimball, Liscak, Roman, Chytka, Tomáš , Alzate, Juan, Kondziolka, Douglas, Moreno, Nuria Martínez , Álvarez, Roberto Martínez , Hallan, David R , Fritch, Chanju, Jareczek, Francis J., Sciscent, Bao Y., Mathieu, David, Carrier, Louis, Abdelsalam, Ahmed, Starke, Robert M., BENJAMIN, CAROLINA, Almeida, Timoteo, Singh, S.P., Lazo, Erwin, Chen, C Y, Esquenazi, Yoshua, Becerril-Gaitan, Andrea, Blanco, Angel I., Palmer, Joshua D., Picozzi, Piero, Lanterna, Luigi Alberto Andrea, Bowden, Greg N., Peterson, Jennifer L., Chiang, Veronica , Pikis, Stylianos , Sheehan, Jason P. , Sheehan, Jason , Tos, Salem M , Mantziaris, Georgios , Shinya, Yuki , Chan, Jason , McDermott, Michael W. , Nabeel, Ahmed M. , Reda, Wael A. , Tawadros, Sameh R. , El-Shehaby, Amr M. N. , Bin-Alamer, Othman , Lunsford, L. Dade , Niranjan, Ajay , Peker, Selçuk , Samancı, Yavuz , Lee, Cheng-chia, Yang, Huai‐Che , Sheehan, Darrah, Sheehan, Kimball , Liščák, Roman , Alzate, Juan Diego , Kondziolka, Douglas, Meng, Ying , Fritch, Chanju , Jareczek, Francis J. , Sciscent, Bao Y. , Mathieu, David , Abdelsalam, Ahmed , Starke, Robert M. , Almeida, Timóteo , Tripathi, Manjul , Speckter, Herwin , Lazo, Erwin , Esquenazi, Yoshua , Becerril‐Gaitan, Andrea , Amsbaugh, Mark J. , Upadhyay, Rituraj , Palmer, Joshua D. , Franzini, Andrea , Picozzi, Piero , Lanterna, Andrea Luigi, Bowden, Greg , Warnick, Ronald E.

Mayo Clinic

Neurosurgery | June 16, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1227/neu.0000000000004136 | PMID 42300133 Get It

BACKGROUND AND OBJECTIVES: Pediatric large-volume brain arteriovenous malformations (AVMs) carry a substantial lifelong hemorrhage risk, neurological symptoms, and treatment morbidity. Single-session stereotactic radiosurgery (SRS) is often unsuitable due to constraints on dose-volume toxicity. Volume-staged SRS (VS-SRS) enables sequential dosing of large nidus volumes, potentially enhancing safety while maintaining efficacy. Evidence in children remains limited. We aimed to evaluate outcomes of VS-SRS for large AVMs in pediatric patients. METHODS: A multicenter retrospective cohort was assembled from 21 centers, including patients aged younger than 21 years treated with VS-SRS for AVMs >10 cm 3 . Clinical and radiological end points included obliteration, hemorrhage, and permanent symptomatic radiation-induced changes (RIC). RESULTS: A total of 103 patients were included (median age 14 years; IQR, 12-17). The median nidus volume at first stage was 18.2 cm 3 (IQR, 12.3-25.6). Median prescription dose per stage was 17 Gy (IQR, 16-18). The median clinical follow-up from the first stage was 57.5 months (IQR, 25-138). Obliteration occurred in 42 of 103 patients (40.8%), with actuarial rates of 6.9% (95% CI: 2.8-14) at 3 years and 29% (95% CI: 20-39) at 5 years. Hemorrhage occurred in 17 of 103 patients (16.5%) during follow-up, and permanent RIC was observed in 9 of 103 patients (8.7%). CONCLUSION: VS-SRS is a reasonably safe, selected option for pediatric large-volume AVMs when microsurgical or endovascular cure is not feasible or prudent. Delivering ≥17 Gy per stage while limiting each treatment volume to <15 cm 3 supports durable nidus control with acceptable toxicity. VS-SRS represents a key modality in multidisciplinary management of this historically difficult-to-treat population.
IL-6 Receptor Blockade as Rescue Therapy in Acute Attacks of MOGAD and AQP4+NMOSD
A, Prera Vilaseca, Bilodeau, Philippe-Antoine, Hellmann, Mark , Jiang, Mulan , Chen, John J., Pittock, Sean J., Levy, Michael, Flanagan, Eoin P., Levy, Michael , Bilodeau, Philippe‐Antoine , Bilodeau, Philippe A , Levy, Michael , Vilaseca, Andreu, Lotan, Itay , Hellmann, Mark, Pittock, Sean J. , Flanagan, Eoin P. , Kister, Ilya

Mayo Clinic

JAMA Neurology | June 15, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1001/jamaneurol.2026.1850 | PMID 42295768 Get It

This case series describes multicenter experience with interleukin 6 (IL-6) receptor blockers used during attacks in aquaporin 4–immunoglobulin G–positive neuromyelitis optica spectrum disorder (AQP4+NMOSD) and myelin oligodendrocyte glycoprotein antibody–associated disease (MOGAD).
Melanoma: Cutaneous, Version 2.2026, NCCN Clinical Practice Guidelines In Oncology
Johnson, Douglas, Albertini, Mark R. , Barker, C. A., Bateni, Sarah, Baumgartner, Joel, Bichakjian, Christopher, Boland, Genevieve , Chandra, Sunandana , Chen, David, Choi, Jacob, DiMaio, Dominick, Dronca, Roxana, Fleming, Martin D. , Galan, Anjela , Guild, Samantha, Hu-Lieskovan, Siwen, Karakousis, Giorgos, Kendra, Kari, Kiuru, Maija, Lange, Julie R., Lanning, Ryan, Logan, Theodore, Materin, Miguel, Nelson, Kelly, Olson, Daniel, Pa, Ott, Puzanov, Igor, Rothermel, Luke, Salama, April K., Shannon, Adrienne, Singh, Arun, Stacey, Andrew, Tsai, Katy, Wuthrick, Evan, Xing, Yan, McMillian, Nicole, Espinosa, Sara, Swetter, Susan M. , Johnson, Douglas B., Barker, Christopher A. , Baumgartner, Joel , Bhatia, Shailender , Bichakjian, Christopher K. , Chmielowski, Bartosz , DiMaio, Dominick J. , Guild, Samantha, Hu‐Lieskovan, Siwen , Karakousis, Giorgos C. , Kiuru, Maija H. , Lanning, Ryan M. , Logan, Theodore F. , Materin, Miguel Angel , Nelson, Kelly C., Olson, Daniel , Olszanski, Anthony J. , Puzanov, Igor , Rothermel, Luke D. , Salama, April K.S. , Sharma, Rohit , Wuthrick, Evan , McMillian, Nicole R.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | June 15, 2026 | Volume: 24 | Issue: 6 | Pages: 272-277

10.6004/jnccn.2026.0027 | PMID 42297031 Get It

The NCCN Guidelines for Melanoma: Cutaneous provide strategies for the diagnosis, treatment, and follow-up of patients with cutaneous melanoma, which is among the most common cancers in the United States. The outcome of cutaneous melanoma is significantly influenced by stage at initial presentation. Generally, localized disease and smaller primary tumors have been associated with more favorable prognosis. Thus, the select content featured in this issue focuses on risk factors associated with cutaneous melanoma development and which should be considered during an initial assessment. These include (1) phenotypic predispositions, (2) personal medical history or comorbidities, (3) genetic predispositions, and (4) environmental factors.
A multimodal foundation model linking histopathology and DNA methylation
Wang, Dianyu , Zhang, J, Chen, Chen, Zhang, Wei , Wang, Song , Guru, Sonpavde, Horbinski, Craig, Tian, Yu , Meng, Yanda , Sonpavde, Guru , Horbinski, Craig

Mayo Clinic

No container title available | June 14, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.06.11.731518 Get It

Abstract Hematoxylin and eosin (H&E) slides are routinely available in cancer care, but molecular profiling often requires additional tissue processing and turnaround time. We introduce HistoMethyl, a DNA methylation-aware pathology foundation model that aligns whole-slide histopathology with matched genome-scale methylation beta-value profiles during pre-training while requiring only an H&E slide at inference. We evaluated HistoMethyl across four task groups: gene mutation prediction, morphology-associated classification, overall survival prediction, and direct DNA methylation beta-value recovery. Evaluation spanned TCGA cross-validation, a disease-held-out lower-grade glioma cohort, and external cohort validation in CPTAC glioblastoma and SurGen rectal adenocarcinoma, totaling 14 cancer cohorts and 81 gene mutation tasks. The best-performing configuration improved mean mutation AUROC by 5.03 percentage points. By converting DNA methylation supervision into an H&E-only representation, His-toMethyl could support an early molecular triage layer that helps prioritize cases for confirmatory sequencing, methylation profiling, immunohistochemistry, and molecular tumor board review. These image-only predictions are intended to accelerate downstream molecular testing and tissue allocation while leaving final diagnosis and treatment selection anchored in validated molecular assays.
Serglycin as a Preliminary Candidate Biomarker in GNE Myopathy Associated with Impaired Secretion and Autophagy Dysregulation
Derksen, Alexa , Dobelmann, Vera , Hentschel, Andreas, Baird, Stephen, Holland, Stephen Henry , Chen, Lei, Ruck, Tobias, Horstkorte, Rüdiger, Milone, Margherita , Roos, Andreas, Hentschel, Andreas , Baird, Stephen D. , Ruck, Tobias , Doles, Jason D. , Evangelista, Teresinha , Spendiff, Sally , Roos, Andreas , Lochmüller, Hanns

Mayo Clinic

No container title available | June 13, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-9791335/v1 Get It

Abstract GNE myopathy (GNEM) is a neuromuscular disorder caused by biallelic mutations in the gene GNE , which encodes a bifunctional enzyme essential for the biosynthesis of sialic acid. Despite extensive characterization, no effective therapies or validated biomarkers exist, and the molecular mechanisms driving disease pathology remain poorly understood. This study identifies the proteoglycan serglycin as a preliminary candidate biomarker in GNEM and investigates the mechanisms underlying its dysregulation. Proteomic analysis of serum samples from GNEM patients revealed reduced circulating serglycin levels. In contrast, increased intracellular serglycin was observed in GNE knockout and GNEM patient iPSC-derived myoblasts, suggesting impaired secretion and/or degradation. To investigate the basis of this accumulation, intracellular trafficking and autophagic pathways were examined. Proteomic profiling from HEK GNE knockout cells revealed alterations in pathways involved in membrane trafficking, Golgi function, and glycoprotein processing, consistent with broader disruptions in the secretory system that may impair serglycin export and contribute to its intracellular retention. In GNEM iPSC-derived myoblasts, serglycin overlapped with LAMP1-positive lysosomal compartments and the ER-phagy receptor FAM134B, suggesting association with lysosomal and ER-phagy related pathways. Functional assays further indicated impaired autophagic flux in mutant cells. Together, these findings support a model in which combined defects in secretion and autophagic clearance contribute to intracellular serglycin accumulation and reduced circulating levels. This study identifies serglycin as a potential circulating biomarker for GNEM and highlights dysregulation of secretory and degradative pathways as converging features of disease pathology.
Vascular Phenotyping in Parkinson’s Disease: Diabetes Mellitus Operationalizes a Microvascular Metabolic Syndrome Cluster Across PPMI Diagnostic Cohorts
Belnavis, Alexander , Chiu, Shannon , Chen, Kewei, Thorpe, Roland J. , Ofori, Edward , Initiative, the Frontotemporal Lobar Degeneration Neuroimaging, Chiu, Shannon Y

Mayo Clinic

No container title available | June 12, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.06.09.26355285 | PMID 42326795 Get It

Abstract Background Diabetes mellitus elevates Parkinson’s disease (PD) risk, via hypothesized cerebrovascular mediation. Whether the diabetes/prediabetes vascular-risk phenotype concentrates in cardiometabolic risk or macrovascular events across prodromal and clinically diagnosed PD remains unresolved. Objectives To quantify the vascular-risk burden associated with diabetes/prediabetes across the PPMI diagnostic cohorts to test whether this association differs by cohort. Methods Cross-sectional analysis of 413 PPMI participants (76 healthy controls, 145 prodromal PD, 192 clinically diagnosed PD) examined diabetes/prediabetes (n = 73) and seven vascular risk factors. The Vascular Burden Score (0 to 7) was a priori partitioned into microvascular and macrovascular sub-scores. Modified Poisson regression estimated adjusted prevalence ratios (aPR), adjusted for age, sex, and body mass index. A cohort-by-diabetes interaction tested cross-cohort consistency. Sensitivity analyses incorporated nigral diffusion tensor imaging (PD-risk biomarker) and FreeSurfer white matter hypointensity volume (cerebrovascular marker). Results Diabetes/prediabetes elevated Vascular Burden Score (β = 0.53, 95% CI 0.29 to 0.77, p < 0.001) versus non-diabetic participants, with a non-significant cohort-by-diabetes interaction (F = 0.29, p = 0.747). Three microvascular factors survived false discovery rate correction: obesity (aPR 2.28), hypertension (aPR 1.60), and hyperlipidemia (aPR 1.45). Macrovascular events showed no diabetic amplification (β = −0.06, p = 0.25). In the imaging-phenotyped subset, Vascular Burden Score components contributed classifier variance distinct from nigral microstructure. Conclusions Diabetes/prediabetes operationalize a microvascular cluster stable across prodromal and idiopathic PD. Cardiometabolic phenotyping may complement established PD-risk biomarkers (dopamine transporter SPECT, nigral diffusion), pending longitudinal validation linking vascular phenotype to dopaminergic markers.
Prediction of immunotherapy response using live tumor fragments from routine clinical biopsies
Braun, David, Dana, Nicholas, Hernan, Hilary R., Scribano, Christina, Johnson, Christin , Vedder, Lindsey, Euw, Erika von , Zweng, Julie, Wargowski, Ellen, Sunil, Aishwarya , Sharma, D, Routh, Josh, Rexroad, Katherine, McDonnell, Payton , Jergens, Victor, Costa, Catarina, Zuniga, Richard, Patel, Paras M., Martin, Robert C.G., Majeed, Umair, Mukhopadhyay, Debabrata, Lou, Yanyan, Kokabi, Nima, Jakub, James W., Hays, David, Godwin, Andrew K., Giffi, Victoria, Gelbard, Alexander, Friedl, Andreas, Duimstra, Emma Kate, Dronca, Roxana S., Chen, Ruqin, Chalfin, Heather, Broome, Barbara , Babiker, Hani M., Chandra, Tarun, Caenepeel, Sean, Hrycyniak, Laura , Sood, Chetan , Ramos, Hilario, Patel, Premal , Advani, Pooja, Gierman, Hinco J., Taube, Janis, Braun, David , Sahni, Shalini, Scribano, Christina M. , Wargowski, Ellen , Zuniga, Richard, Toia, Giuseppe V. , Martin, Robert C.G. , Majeed, Umair , Mukhopadhyay, Debabrata , Lou, Yanyan , Kokabi, Nima , Jakub, James W. , Godwin, Andrew K. , Gelbard, Alexander , Friedl, Andreas , Dronca, Roxana , Chen, Ruqin, Chalfin, Heather J., Babiker, Hani M. , Caenepeel, Sean , Ramos, Hilario J. , Patel, Premal, Advani, Pooja , Gierman, Hinco J. , Taube, Janis M

Mayo Clinic

No container title available | June 11, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.06.05.26354635 Get It

Summary Functional ex vivo assays using live tumor tissues have demonstrated strong predictive accuracy for response to immune checkpoint inhibitors (ICIs) but are not scalable, requiring manual processing of large resections collected at academic centers. Here, an ex vivo live tumor fragment (LTF) platform was developed using standard-of-care biopsies from 228 patients with suspected malignancy collected across prospective, multicenter observational trials and biobanks. Hierarchical clustering of ICI-mediated changes in cytokine production identified two groups: responders and nonresponders. A binary classifier (elive index) using 8 cytokines achieved an AUC of 0.99 for cluster prediction. elive index correctly predicted clinical benefit in 93% (26/28) of patients ( P = 3.2x10 -5 ) and accurately identified 83% (10/12) of objective responders. Critically, elive responders were identified among biomarker-negative patients, highlighting the platform as a scalable approach that complements existing companion diagnostics and expands the population of patients identified to benefit from ICI therapy.
Tocilizumab as Add-on Therapy for Severe Attacks in NMOSD and MOGAD: A Multicenter Retrospective Case Series (P3-1.009)
Flanagan, Eoin P., Vilaseca, Andreu, Bilodeau, Philippe-Antoine, Jiang, Mulan , Said, Yana , Chen, Haiwen , Chen, John J., Pittock, Sean J., Sotirchos, Elias, Levy, Michael, Flanagan, Eoin P. , Vilaseca, Andreu , Bilodeau, Philippe-Antoine, Filippatou, Angeliki , Pittock, Sean J. , Sotirchos, Elias S. , Levy, Michael , Kister, Ilya

Mayo Clinic

Neurology | June 10, 2026 | Volume: 106 | Issue: 11_Supplement_1 | Pages: No page available

10.1212/wnl.0000000000217046 Get It

Uncovering the Neurological Substrates Underlying Restlessness in Cluster Headache – A Functional MRI Study (P6-15.012)
Chen, Yung-Lin, Chen, Mei‐Chun , Lau, Chi-ieong David, Chen, Shu‐Ting , Wu, Jr‐Wei , Chiang, Chia‐Chun

Mayo Clinic

Neurology | June 10, 2026 | Volume: 106 | Issue: 11_Supplement_1 | Pages: No page available

10.1212/wnl.0000000000215324 Get It